HRP20171592T1 - Postupci i pripravci namijenjeni primjeni moksifloksacina u uho - Google Patents
Postupci i pripravci namijenjeni primjeni moksifloksacina u uho Download PDFInfo
- Publication number
- HRP20171592T1 HRP20171592T1 HRP20171592TT HRP20171592T HRP20171592T1 HR P20171592 T1 HRP20171592 T1 HR P20171592T1 HR P20171592T T HRP20171592T T HR P20171592TT HR P20171592 T HRP20171592 T HR P20171592T HR P20171592 T1 HRP20171592 T1 HR P20171592T1
- Authority
- HR
- Croatia
- Prior art keywords
- formulation
- intended
- accordance
- tympanic membrane
- moxifloxacin
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 31
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 title claims 6
- 229960003702 moxifloxacin Drugs 0.000 title claims 6
- 238000009472 formulation Methods 0.000 claims 30
- 210000003454 tympanic membrane Anatomy 0.000 claims 9
- 239000003795 chemical substances by application Substances 0.000 claims 7
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical group O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims 6
- 229920002125 Sokalan® Polymers 0.000 claims 6
- 239000003961 penetration enhancing agent Substances 0.000 claims 5
- 239000002202 Polyethylene glycol Substances 0.000 claims 4
- 239000004584 polyacrylic acid Substances 0.000 claims 4
- 229920001223 polyethylene glycol Polymers 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 3
- PQUXFUBNSYCQAL-UHFFFAOYSA-N 1-(2,3-difluorophenyl)ethanone Chemical compound CC(=O)C1=CC=CC(F)=C1F PQUXFUBNSYCQAL-UHFFFAOYSA-N 0.000 claims 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims 2
- 229920002148 Gellan gum Polymers 0.000 claims 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical group C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 2
- 229920002845 Poly(methacrylic acid) Polymers 0.000 claims 2
- GAMPNQJDUFQVQO-UHFFFAOYSA-N acetic acid;phthalic acid Chemical compound CC(O)=O.OC(=O)C1=CC=CC=C1C(O)=O GAMPNQJDUFQVQO-UHFFFAOYSA-N 0.000 claims 2
- 229920002301 cellulose acetate Polymers 0.000 claims 2
- 210000000959 ear middle Anatomy 0.000 claims 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 2
- 239000004816 latex Substances 0.000 claims 2
- 229920000126 latex Polymers 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- QNILTEGFHQSKFF-UHFFFAOYSA-N n-propan-2-ylprop-2-enamide Chemical compound CC(C)NC(=O)C=C QNILTEGFHQSKFF-UHFFFAOYSA-N 0.000 claims 2
- 229920001983 poloxamer Polymers 0.000 claims 2
- 229960000502 poloxamer Drugs 0.000 claims 2
- 229920001987 poloxamine Polymers 0.000 claims 2
- 229940047670 sodium acrylate Drugs 0.000 claims 2
- 239000000661 sodium alginate Substances 0.000 claims 2
- 235000010413 sodium alginate Nutrition 0.000 claims 2
- 229940005550 sodium alginate Drugs 0.000 claims 2
- 206010050337 Cerumen impaction Diseases 0.000 claims 1
- 230000003444 anaesthetic effect Effects 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 239000013011 aqueous formulation Substances 0.000 claims 1
- 239000000227 bioadhesive Substances 0.000 claims 1
- 210000002939 cerumen Anatomy 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 239000003230 hygroscopic agent Substances 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 230000035699 permeability Effects 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
Claims (15)
1. Formulacija, naznačena time što je namijenjena upotrebi primjenom na membranu bubnjića,
gdje je navedena formulacija vodena i sadrži viskogeno sredstvo i moksifloksacin, ili njegova sol;
gdje je navedena formulacija tekuća i ima viskoznost manju od 100 Pa*s na 25 °C;
gdje navedena formulacija, nakon primjene na navedenu membranu bubnjića, tvori gel koji ima elastičnu čvrstoću dovoljnu za zadržavanje navedene formulacije na navedenoj membrani bubnjića; i
gdje navedeni moksifloksacin prolazi kroz membranu bubnjića i u prostor srednjeg uha kada se formulaciju primijenjuje na membranu bubnjića.;
2. Formulacija, namijenjena upotrebi u skladu s patentnim zahtjevom 1, naznačena time što je navedeno viskogeno sredstvo:
(a) gelan;
(b) N-izopropilakrilamid s natrijevim akrilatom i n-N-alkilakrilamidom;
(c) poliakrilna kiselina s polietilen-glikolom;
(d) polimetakrilna kiselina s polietilen-glikolom;
(e) CARBOPOL® (poliakrilna kiselina) s hidroksipropilmetilcelulozom;
(f) celuloznoacetatno-hidrogenftalatni lateks; ili
(g) natrijev alginat.;
3. Formulacija, namijenjena upotrebi u skladu s patentnim zahtjevom 1, naznačena time što je navedeno viskogeno sredstvo inverzni duromerni gel.;
4. Formulacija, namijenjena upotrebi u skladu s patentnim zahtjevom 3, naznačena time što je navedeno viskogeno sredstvo poloksamer ili poloksamin.;
5. Formulacija, namijenjena upotrebi u skladu s patentnim zahtjevom 1, naznačena time što dodatno sadrži protuupalno sredstvo, anestetik, pojačivač prianjanja, pojačivač propusnosti ili prodornosti, bioadheziv, higroskopno sredstvo, omekšivač ušnog voska, ili konzervans.;
6. Formulacija, namijenjena upotrebi u skladu s patentnim zahtjevom 1, naznačena time što dodatno sadrži pojačivač prodornosti.;
7. Formulacija, namijenjena upotrebi u skladu s patentnim zahtjevom 6, naznačen time što je pojačivač prodornosti izopropil-miristat (IPM).;
8. Formulacija, namijenjena upotrebi u skladu s patentnim zahtjevom 1, naznačena time što je formulacija namijenjena upotrebi u kombinaciji s pojačivačem prodornosti kao predliječenje, te što je pojačivač prodornosti izopropil-miristat (IPM).;
9. Vodena formulacija, naznačena time što sadrži viskogeno sredstvo, moksifloksacin, ili njegovu sol, te izopropil-miristat (IPM),
gdje je navedena formulacija tekuća i ima viskoznost manju od 100 Pa*s na 25 °C;
gdje navedena formulacija, nakon primjene na membranu bubnjića u uhu subjekta, tvori gel koji ima elastičnu čvrstoću dovoljnu za zadržavanje navedene formulacije na membrani bubnjića; i
gdje navedeni moksifloksacin prolazi kroz membranu bubnjića i u prostor srednjeg uha kada se formulaciju primijenjuje na membranu bubnjića.
10. Formulacija u skladu s patentnim zahtjevom 9, naznačena time što je navedeno viskogeno sredstvo:
(a) gelan;
(b) N-izopropilakrilamid s natrijevim akrilatom i n-N-alkilakrilamidom;
(c) poliakrilna kiselina s polietilen-glikolom;
(d) polimetakrilna kiselina s polietilen-glikolom;
(e) CARBOPOL® (poliakrilna kiselina) s hidroksipropilmetilcelulozom;
(f) celuloznoacetatno-hidrogenftalatni lateks; ili
(g) natrijev alginat.
11. Formulacija u skladu s patentnim zahtjevom 9, naznačena time što je navedeno viskogeno sredstvo inverzni duromerni gel.
12. Formulacija u skladu s patentnim zahtjevom 11, naznačena time što je navedeno viskogeno sredstvo poloksamer ili poloksamin.
13. Formulacija u skladu s patentnim zahtjevom 9, ili formulacija namijenjena upotrebi u skladu s patentnim zahtjevom 1, naznačene time što formulacija sadrži 10% do 40% viskogenog sredstva.
14. Formulacija u skladu s patentnim zahtjevom 9, ili formulacija namijenjena upotrebi u skladu s patentnim zahtjevom 1, naznačene time što formulacija sadrži 20% do 30% viskogenog sredstva.
15. Formulacija u skladu s patentnim zahtjevom 9, ili formulacija namijenjena upotrebi u skladu s patentnim zahtjevom 1, naznačene time što formulacija sadrži 1% do 3% moksifloksacina, ili njegove soli.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29301910P | 2010-01-07 | 2010-01-07 | |
PCT/US2011/020531 WO2011085209A2 (en) | 2010-01-07 | 2011-01-07 | Methods and compositions for applying moxifloxacin to the ear |
EP11732210.7A EP2521547B1 (en) | 2010-01-07 | 2011-01-07 | Methods and compositions for applying moxifloxacin to the ear |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20171592T1 true HRP20171592T1 (hr) | 2018-02-09 |
Family
ID=44306169
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20171592TT HRP20171592T1 (hr) | 2010-01-07 | 2017-10-18 | Postupci i pripravci namijenjeni primjeni moksifloksacina u uho |
Country Status (23)
Country | Link |
---|---|
US (1) | US20120289541A1 (hr) |
EP (2) | EP2521547B1 (hr) |
JP (3) | JP2013516485A (hr) |
KR (2) | KR101835895B1 (hr) |
CN (2) | CN106309356A (hr) |
AU (1) | AU2011204275B2 (hr) |
BR (1) | BR112012016809A2 (hr) |
CA (1) | CA2786525A1 (hr) |
CL (1) | CL2012001835A1 (hr) |
CY (1) | CY1119493T1 (hr) |
DK (1) | DK2521547T3 (hr) |
ES (1) | ES2644826T3 (hr) |
HR (1) | HRP20171592T1 (hr) |
HU (1) | HUE035586T2 (hr) |
LT (1) | LT2521547T (hr) |
MX (1) | MX337419B (hr) |
NO (1) | NO2521547T3 (hr) |
PL (1) | PL2521547T3 (hr) |
PT (1) | PT2521547T (hr) |
RU (2) | RU2016101214A (hr) |
SI (1) | SI2521547T1 (hr) |
WO (1) | WO2011085209A2 (hr) |
ZA (1) | ZA201205965B (hr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7220431B2 (en) * | 2002-11-27 | 2007-05-22 | Regents Of The University Of Minnesota | Methods and compositions for applying pharmacologic agents to the ear |
DK2844309T3 (da) * | 2012-06-28 | 2022-01-24 | The Administrators Of The Tulane Educational Fund | Selektivt polymeriserbare sammensætninger |
CN103869033B (zh) * | 2012-12-14 | 2016-10-05 | 南京长澳医药科技有限公司 | 一种液相色谱法分离测定盐酸莫西沙星及其杂质的方法 |
JP6255134B1 (ja) * | 2016-11-02 | 2017-12-27 | ヴェローチェ・バイオファーマ・エルエルシー | 耳炎の治療のための組成物および方法 |
WO2019113425A1 (en) * | 2017-12-08 | 2019-06-13 | The Johns Hopkins University | Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces |
CN108593696B (zh) * | 2018-04-26 | 2020-11-03 | 南京明捷生物医药检测有限公司 | 一种利用定量核磁测定多肽中三氟乙酸残留的方法 |
CN117045593B (zh) * | 2023-09-19 | 2024-05-28 | 上海市第六人民医院 | 一种用于慢性中耳炎治疗的抗菌温敏水凝胶及其制备方法和应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6201072B1 (en) | 1997-10-03 | 2001-03-13 | Macromed, Inc. | Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties |
US6740664B2 (en) * | 1998-09-30 | 2004-05-25 | Alcon, Inc. | Methods for treating otic and ophthalmic infections |
AR020661A1 (es) * | 1998-09-30 | 2002-05-22 | Alcon Lab Inc | Una composicion farmaceutica topica oftalmica, otica o nasal y el uso de la misma para la manufactura de un medicamento |
JP3450805B2 (ja) * | 2000-08-08 | 2003-09-29 | わかもと製薬株式会社 | 水性医薬組成物 |
US7220431B2 (en) * | 2002-11-27 | 2007-05-22 | Regents Of The University Of Minnesota | Methods and compositions for applying pharmacologic agents to the ear |
CN101072571A (zh) * | 2004-12-10 | 2007-11-14 | 爱尔康公司 | 用于治疗耳感染的组合物 |
WO2009142719A2 (en) * | 2008-05-19 | 2009-11-26 | Massachusetts Institute Of Technology | Tympanic membrane permeating ear drops and uses thereof |
-
2011
- 2011-01-07 RU RU2016101214A patent/RU2016101214A/ru not_active Application Discontinuation
- 2011-01-07 MX MX2012007928A patent/MX337419B/es active IP Right Grant
- 2011-01-07 PL PL11732210T patent/PL2521547T3/pl unknown
- 2011-01-07 ES ES11732210.7T patent/ES2644826T3/es active Active
- 2011-01-07 DK DK11732210.7T patent/DK2521547T3/da active
- 2011-01-07 JP JP2012548156A patent/JP2013516485A/ja active Pending
- 2011-01-07 RU RU2012133568/15A patent/RU2576029C2/ru not_active IP Right Cessation
- 2011-01-07 KR KR1020127020775A patent/KR101835895B1/ko active IP Right Grant
- 2011-01-07 EP EP11732210.7A patent/EP2521547B1/en active Active
- 2011-01-07 US US13/520,519 patent/US20120289541A1/en not_active Abandoned
- 2011-01-07 PT PT117322107T patent/PT2521547T/pt unknown
- 2011-01-07 NO NO11732210A patent/NO2521547T3/no unknown
- 2011-01-07 HU HUE11732210A patent/HUE035586T2/en unknown
- 2011-01-07 AU AU2011204275A patent/AU2011204275B2/en not_active Ceased
- 2011-01-07 EP EP17186323.6A patent/EP3305280A1/en not_active Withdrawn
- 2011-01-07 CA CA2786525A patent/CA2786525A1/en not_active Abandoned
- 2011-01-07 LT LTEP11732210.7T patent/LT2521547T/lt unknown
- 2011-01-07 WO PCT/US2011/020531 patent/WO2011085209A2/en active Application Filing
- 2011-01-07 KR KR1020187005804A patent/KR20180027611A/ko not_active Application Discontinuation
- 2011-01-07 BR BR112012016809A patent/BR112012016809A2/pt not_active Application Discontinuation
- 2011-01-07 SI SI201131326T patent/SI2521547T1/en unknown
- 2011-01-07 CN CN201610909298.7A patent/CN106309356A/zh not_active Withdrawn
- 2011-01-07 CN CN2011800127647A patent/CN102791270A/zh active Pending
-
2012
- 2012-07-06 CL CL2012001835A patent/CL2012001835A1/es unknown
- 2012-08-07 ZA ZA2012/05965A patent/ZA201205965B/en unknown
-
2016
- 2016-02-05 JP JP2016020395A patent/JP6267246B2/ja not_active Expired - Fee Related
-
2017
- 2017-10-18 CY CY20171101086T patent/CY1119493T1/el unknown
- 2017-10-18 HR HRP20171592TT patent/HRP20171592T1/hr unknown
- 2017-12-21 JP JP2017245040A patent/JP2018076352A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20171592T1 (hr) | Postupci i pripravci namijenjeni primjeni moksifloksacina u uho | |
HRP20200434T1 (hr) | Stabilne vodene formulacije adalimumaba | |
RU2012146100A (ru) | Легко дозируемый твердый препарат | |
JOP20200148B1 (ar) | تركيبة عقار ذو إطلاق متأخر | |
JP2011217414A5 (hr) | ||
CL2010001193A1 (es) | Un método y sistema para proveer una sesión ip (internet protocol) en un agente extranjero, desde un agente domestico a un nodo móvil ofreciendo una dirección dinámica virtual (virtual care of adress), y un elemento de red. | |
WO2014186742A3 (en) | Anhydrous hydrogel composition | |
BR112013015796A2 (pt) | composição de agente de formação de imagem, método de preparar uma composição de agente de formação de imagem, método de preparar um quelante 18f-nota, e, composição farmacêutica. | |
BR112014010814A8 (pt) | composições de herbicida/fitoprotetor contendo amidas do ácido n-(tetrazol-5-il) aril carboxílico e amidas do ácido n-(triazol-5-il) aril carboxílico | |
HRP20220626T1 (hr) | Otopine bimatoprosta i timolola bez konzervansa | |
MY172413A (en) | Fungicide formulations for soft pvc | |
JP2013516485A5 (hr) | ||
MX2016004276A (es) | Coformulaciones de bifentrina con agentes protectores de cultivo de alta fusion para uso con fertilizantes liquidos. | |
JP2015532923A5 (hr) | ||
MX336777B (es) | Peliculas y composiciones que comprenden las mismas. | |
EA201300176A2 (ru) | Композиция контрастной среды с эффектом контрастного усиления включением высококонцентрированного контрастного агента | |
BR112013015798A2 (pt) | composição de agente de formação de imagem, método de preparar uma composição de agente de formação de imagem, e, composição farmacêutica | |
EP3332439A4 (en) | FLOWABLE BATTERY ELECTROLYTE COMPOSITIONS CONTAINING ORGANOSULFATE WETTING AGENT AND FLOW BATTERIES COMPRISING THE SAME | |
WO2014204854A8 (en) | Compositions and methods for the preparation of kidney protective agents comprising amifostine and amino acids | |
WO2014184662A3 (en) | Antiemetic extended release solid dosage forms | |
FR2958799B1 (fr) | Bandelettes de liaison d'anodes et de cathodes d'un convertisseur electrochimique et convertisseur le comprenant | |
MA40310A1 (fr) | Formulation et utilisation d'insecticide | |
MX358604B (es) | Composicion liquida acuosa que contiene acido 2-amino-3-(4-bromobenzoil) fenilacetico. | |
WO2018178478A3 (es) | Formulaciones lubricantes vaginales | |
BRPI0915455A2 (pt) | ácido eprosartan, composição farmacêutica, formulação farmacêutica, e, uso de ácido eprosartan |